View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 27, 2022

Astellas and Seagen report positive Phase Ib/II urothelial cancer data

The combination therapy offered a confirmed objective response rate per BICR of 64.5% in Cohort K of the EV-103 trial.

Astellas Pharma and Seagen have reported positive topline data from the Phase Ib/II EV-103 clinical trial (KEYNOTE-869) Cohort K of Padcev (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) as first-line therapy for unresectable locally advanced or metastatic urothelial cancer (la/mUC) patients. 

A randomised cohort, EV-103 Cohort K is analysing enfortumab vedotin alone or along with pembrolizumab as first-line therapy for unresectable la/mUC patients, ineligible for cisplatin-based chemotherapy. 

According to the trial findings from this cohort, the combination therapy offered a confirmed objective response rate (ORR) per blinded independent central review (BICR) of 64.5%, the primary endpoint. 

Astellas noted that the median duration of response (DOR) per BICR was not attained. 

Rash maculo-papular, anaemia, lipase increased and urinary tract infection among others were the most commonly reported treatment-emergent adverse events Grade 3 or greater reported in over 5% of trial subjects. 

These results are generally in line with priorly reported efficacy and safety data from the EV-103 dose-escalation cohort and expansion Cohort A.

Astellas Development Therapeutic Areas senior vice-president and head Ahsan Arozullah said: “Approximately half of patients with advanced urothelial carcinoma are ineligible for cisplatin-based chemotherapy. 

“We intend to discuss Cohort K results with regulatory authorities as we seek to develop a new first-line treatment combination for these patients.”

Keytruda is an anti-PD-1 therapy of Merck.

Currently, Astellas, Seagen and Merck are analysing enfortumab vedotin plus pembrolizumab as part of a partnership, which includes three Phase III trials.

In May last year, Astellas and Seagen reported data from EV-201 and EV-103 trials where Padcev offered durable responses in locally advanced or metastatic urothelial cancer patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena